Risk of Leukemia after Chemotherapy and Radiation Treatment for Breast Cancer. Curtis, R. E., Boice, J. D., Stovall, M., Bernstein, L., Greenberg, R. S., Flannery, J. T., Schwartz, A. G., Weyer, P., Moloney, W. C., & Hoover, R. N. New England Journal of Medicine, 326(26):1745--1751, 1992. ![Risk of Leukemia after Chemotherapy and Radiation Treatment for Breast Cancer [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex SINCE the mid-1970s adjuvant chemotherapy has been widely used to treat breast cancer with regional lymph-node involvement.1 More recently, systemic drug therapy has been given to women with localized disease, most of whom survive for many years without a recurrence of cancer.2 Patients with breast cancer who are treated with chemotherapy, particularly regimens containing melphalan, are at increased risk of secondary leukemia.3 4 5 However, the risk associated with cyclophosphamide, the primary alkylating agent used today to treat breast cancer, has not been well explored. Moreover, there are few studies describing the dose–response relation of these drugs, their interaction with radiotherapy, and . . .
@article{curtis_risk_1992,
title = {Risk of {Leukemia} after {Chemotherapy} and {Radiation} {Treatment} for {Breast} {Cancer}},
volume = {326},
issn = {0028-4793},
url = {http://www.nejm.org/doi/full/10.1056/NEJM199206253262605},
doi = {10.1056/NEJM199206253262605},
abstract = {SINCE the mid-1970s adjuvant chemotherapy has been widely used to treat breast cancer with regional lymph-node involvement.1 More recently, systemic drug therapy has been given to women with localized disease, most of whom survive for many years without a recurrence of cancer.2 Patients with breast cancer who are treated with chemotherapy, particularly regimens containing melphalan, are at increased risk of secondary leukemia.3 4 5 However, the risk associated with cyclophosphamide, the primary alkylating agent used today to treat breast cancer, has not been well explored. Moreover, there are few studies describing the dose–response relation of these drugs, their interaction with radiotherapy, and . . .},
number = {26},
urldate = {2013-04-13},
journal = {New England Journal of Medicine},
author = {Curtis, Rochelle E. and Boice, John D. and Stovall, Marilyn and Bernstein, Leslie and Greenberg, Raymond S. and Flannery, John T. and Schwartz, Ann G. and Weyer, Peter and Moloney, William C. and Hoover, Robert N.},
year = {1992},
pmid = {1594016},
pages = {1745--1751},
file = {Full Text PDF:files/38239/Curtis et al. - 1992 - Risk of Leukemia after Chemotherapy and Radiation .pdf:application/pdf}
}
Downloads: 0
{"_id":"xwhHRirgkzih4bZsj","bibbaseid":"curtis-boice-stovall-bernstein-greenberg-flannery-schwartz-weyer-etal-riskofleukemiaafterchemotherapyandradiationtreatmentforbreastcancer-1992","downloads":0,"creationDate":"2016-09-09T06:27:31.686Z","title":"Risk of Leukemia after Chemotherapy and Radiation Treatment for Breast Cancer","author_short":["Curtis, R. E.","Boice, J. D.","Stovall, M.","Bernstein, L.","Greenberg, R. S.","Flannery, J. T.","Schwartz, A. G.","Weyer, P.","Moloney, W. C.","Hoover, R. N."],"year":1992,"bibtype":"article","biburl":"https://www.sfu.ca/~howlett/howlett16.bib","bibdata":{"bibtype":"article","type":"article","title":"Risk of Leukemia after Chemotherapy and Radiation Treatment for Breast Cancer","volume":"326","issn":"0028-4793","url":"http://www.nejm.org/doi/full/10.1056/NEJM199206253262605","doi":"10.1056/NEJM199206253262605","abstract":"SINCE the mid-1970s adjuvant chemotherapy has been widely used to treat breast cancer with regional lymph-node involvement.1 More recently, systemic drug therapy has been given to women with localized disease, most of whom survive for many years without a recurrence of cancer.2 Patients with breast cancer who are treated with chemotherapy, particularly regimens containing melphalan, are at increased risk of secondary leukemia.3 4 5 However, the risk associated with cyclophosphamide, the primary alkylating agent used today to treat breast cancer, has not been well explored. Moreover, there are few studies describing the dose–response relation of these drugs, their interaction with radiotherapy, and . . .","number":"26","urldate":"2013-04-13","journal":"New England Journal of Medicine","author":[{"propositions":[],"lastnames":["Curtis"],"firstnames":["Rochelle","E."],"suffixes":[]},{"propositions":[],"lastnames":["Boice"],"firstnames":["John","D."],"suffixes":[]},{"propositions":[],"lastnames":["Stovall"],"firstnames":["Marilyn"],"suffixes":[]},{"propositions":[],"lastnames":["Bernstein"],"firstnames":["Leslie"],"suffixes":[]},{"propositions":[],"lastnames":["Greenberg"],"firstnames":["Raymond","S."],"suffixes":[]},{"propositions":[],"lastnames":["Flannery"],"firstnames":["John","T."],"suffixes":[]},{"propositions":[],"lastnames":["Schwartz"],"firstnames":["Ann","G."],"suffixes":[]},{"propositions":[],"lastnames":["Weyer"],"firstnames":["Peter"],"suffixes":[]},{"propositions":[],"lastnames":["Moloney"],"firstnames":["William","C."],"suffixes":[]},{"propositions":[],"lastnames":["Hoover"],"firstnames":["Robert","N."],"suffixes":[]}],"year":"1992","pmid":"1594016","pages":"1745--1751","file":"Full Text PDF:files/38239/Curtis et al. - 1992 - Risk of Leukemia after Chemotherapy and Radiation .pdf:application/pdf","bibtex":"@article{curtis_risk_1992,\n\ttitle = {Risk of {Leukemia} after {Chemotherapy} and {Radiation} {Treatment} for {Breast} {Cancer}},\n\tvolume = {326},\n\tissn = {0028-4793},\n\turl = {http://www.nejm.org/doi/full/10.1056/NEJM199206253262605},\n\tdoi = {10.1056/NEJM199206253262605},\n\tabstract = {SINCE the mid-1970s adjuvant chemotherapy has been widely used to treat breast cancer with regional lymph-node involvement.1 More recently, systemic drug therapy has been given to women with localized disease, most of whom survive for many years without a recurrence of cancer.2 Patients with breast cancer who are treated with chemotherapy, particularly regimens containing melphalan, are at increased risk of secondary leukemia.3 4 5 However, the risk associated with cyclophosphamide, the primary alkylating agent used today to treat breast cancer, has not been well explored. Moreover, there are few studies describing the dose–response relation of these drugs, their interaction with radiotherapy, and . . .},\n\tnumber = {26},\n\turldate = {2013-04-13},\n\tjournal = {New England Journal of Medicine},\n\tauthor = {Curtis, Rochelle E. and Boice, John D. and Stovall, Marilyn and Bernstein, Leslie and Greenberg, Raymond S. and Flannery, John T. and Schwartz, Ann G. and Weyer, Peter and Moloney, William C. and Hoover, Robert N.},\n\tyear = {1992},\n\tpmid = {1594016},\n\tpages = {1745--1751},\n\tfile = {Full Text PDF:files/38239/Curtis et al. - 1992 - Risk of Leukemia after Chemotherapy and Radiation .pdf:application/pdf}\n}\n\n","author_short":["Curtis, R. E.","Boice, J. D.","Stovall, M.","Bernstein, L.","Greenberg, R. S.","Flannery, J. T.","Schwartz, A. G.","Weyer, P.","Moloney, W. C.","Hoover, R. N."],"key":"curtis_risk_1992","id":"curtis_risk_1992","bibbaseid":"curtis-boice-stovall-bernstein-greenberg-flannery-schwartz-weyer-etal-riskofleukemiaafterchemotherapyandradiationtreatmentforbreastcancer-1992","role":"author","urls":{"Paper":"http://www.nejm.org/doi/full/10.1056/NEJM199206253262605"},"downloads":0},"search_terms":["risk","leukemia","chemotherapy","radiation","treatment","breast","cancer","curtis","boice","stovall","bernstein","greenberg","flannery","schwartz","weyer","moloney","hoover"],"keywords":[],"authorIDs":[],"dataSources":["Bn7xRaKMY43f7hFwh"]}